MX376072B - 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa - Google Patents
3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasaInfo
- Publication number
- MX376072B MX376072B MX2018007755A MX2018007755A MX376072B MX 376072 B MX376072 B MX 376072B MX 2018007755 A MX2018007755 A MX 2018007755A MX 2018007755 A MX2018007755 A MX 2018007755A MX 376072 B MX376072 B MX 376072B
- Authority
- MX
- Mexico
- Prior art keywords
- azabiciclo
- hexanes
- substituted
- ketohexokinase inhibitors
- ketohexokinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
En la presente se proporcionan 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa, procesos para la elaboración de estos compuestos, y métodos que comprenden administrar estos compuestos a un mamífero que lo necesita.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562272598P | 2015-12-29 | 2015-12-29 | |
| US201662423549P | 2016-11-17 | 2016-11-17 | |
| PCT/IB2016/057728 WO2017115205A1 (en) | 2015-12-29 | 2016-12-16 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018007755A MX2018007755A (es) | 2018-11-09 |
| MX376072B true MX376072B (es) | 2025-03-07 |
Family
ID=57755415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007755A MX376072B (es) | 2015-12-29 | 2016-12-16 | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa |
Country Status (38)
| Country | Link |
|---|---|
| US (6) | US9809579B2 (es) |
| EP (1) | EP3397631B1 (es) |
| JP (1) | JP6503515B2 (es) |
| KR (1) | KR102073048B1 (es) |
| CN (1) | CN108473469B (es) |
| AU (1) | AU2016380920B2 (es) |
| CA (1) | CA2952466C (es) |
| CL (1) | CL2018001667A1 (es) |
| CO (1) | CO2018006714A2 (es) |
| CU (1) | CU24540B1 (es) |
| CY (1) | CY1124389T1 (es) |
| DK (1) | DK3397631T3 (es) |
| EC (1) | ECSP18048517A (es) |
| ES (1) | ES2871251T3 (es) |
| GE (2) | GEP20207147B (es) |
| HR (1) | HRP20210769T1 (es) |
| HU (1) | HUE054380T2 (es) |
| IL (1) | IL260330B (es) |
| LT (1) | LT3397631T (es) |
| MA (1) | MA43518B1 (es) |
| MD (1) | MD3397631T2 (es) |
| MX (1) | MX376072B (es) |
| NI (1) | NI201800072A (es) |
| PE (1) | PE20181289A1 (es) |
| PH (1) | PH12018501375A1 (es) |
| PL (1) | PL3397631T3 (es) |
| PT (1) | PT3397631T (es) |
| RS (1) | RS61896B1 (es) |
| RU (1) | RU2696269C1 (es) |
| SG (1) | SG11201804363UA (es) |
| SI (1) | SI3397631T1 (es) |
| SV (1) | SV2018005709A (es) |
| TN (1) | TN2018000198A1 (es) |
| TW (1) | TWI653232B (es) |
| UA (1) | UA121271C2 (es) |
| UY (1) | UY37051A (es) |
| WO (1) | WO2017115205A1 (es) |
| ZA (1) | ZA201803449B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2018000198A1 (en) | 2015-12-29 | 2019-10-04 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
| IL264955B (en) | 2016-09-02 | 2022-06-01 | Ironwood Pharmaceuticals Inc | Fused bicyclic sgc stimulators |
| US10558874B1 (en) | 2017-01-19 | 2020-02-11 | State Farm Mutual Automobile Insurance Company | Apparatuses, systems and methods for generation and transmission of vehicle operation mode data |
| CN109316601B (zh) * | 2017-07-31 | 2021-11-09 | 武汉朗来科技发展有限公司 | 药物组合物及其用途 |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| JP7161605B2 (ja) * | 2018-08-31 | 2022-10-26 | ファイザー・インク | Nash/nafldおよび関連疾患の治療のための組合せ |
| TWI714231B (zh) | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
| KR102558308B1 (ko) * | 2018-09-27 | 2023-07-24 | 주식회사 엘지화학 | 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물 |
| WO2020156445A1 (zh) * | 2019-01-29 | 2020-08-06 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂及其用途 |
| US20220184172A1 (en) * | 2019-04-19 | 2022-06-16 | The Regents Of The University Of California | Ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| CN111978296A (zh) * | 2019-05-22 | 2020-11-24 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂及其用途 |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| BR112021024108A2 (pt) | 2019-05-31 | 2022-03-22 | Ikena Oncology Inc | Inibidores de tead e usos dos mesmos |
| TWI750685B (zh) | 2019-06-17 | 2021-12-21 | 美商美國禮來大藥廠 | 二取代吡唑化合物 |
| CA3163979A1 (en) | 2019-12-10 | 2021-06-17 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| WO2021129737A1 (zh) | 2019-12-24 | 2021-07-01 | 南京明德新药研发有限公司 | 具有khk抑制作用的化合物 |
| WO2021129817A1 (zh) * | 2019-12-25 | 2021-07-01 | 南京明德新药研发有限公司 | 具有果糖激酶(khk)抑制作用的嘧啶类化合物 |
| GB202001856D0 (en) * | 2020-02-11 | 2020-03-25 | Inorbit Therapeutics Ab | Compounds useful in inhibiting ketohexokinase and methods of making and using the same |
| US12479829B2 (en) | 2020-02-13 | 2025-11-25 | Eli Lilly And Company | 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds |
| JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Nafld/nashおよび関連疾患の処置のための組合せ |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
| MX2022010811A (es) | 2020-03-27 | 2022-09-27 | Pfizer | Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin -1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxil ico o una sal farmaceutica del mismo. |
| EP4134366A4 (en) * | 2020-04-20 | 2023-10-11 | Lg Chem, Ltd. | 3-AZABICYCLOALKYL DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME |
| CN111423420A (zh) * | 2020-04-30 | 2020-07-17 | 广州博济医药生物技术股份有限公司 | 作为己酮糖激酶抑制剂的并环化合物 |
| CN113754640B (zh) * | 2020-06-03 | 2023-02-14 | 山东轩竹医药科技有限公司 | 氘代的己酮糖激酶抑制剂及其用途 |
| WO2022022476A1 (zh) * | 2020-07-28 | 2022-02-03 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂的盐、晶型及其用途 |
| AU2021341508A1 (en) | 2020-09-10 | 2023-05-25 | Precirix N.V. | Antibody fragment against fap |
| CN114181198B (zh) * | 2020-09-15 | 2025-07-15 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类己酮糖激酶抑制剂及其用途 |
| EP4269404A4 (en) * | 2020-12-25 | 2024-12-04 | Xizang Haisco Pharmaceutical Co., Ltd. | KETOHEXOKINASE INHIBITORS AND USE THEREOF |
| ES3061522T3 (en) | 2021-03-29 | 2026-04-06 | Gilead Sciences Inc | Khk inhibitors |
| KR20220136939A (ko) | 2021-04-01 | 2022-10-11 | 주식회사 엘지화학 | 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물 |
| WO2022262841A1 (zh) * | 2021-06-17 | 2022-12-22 | 杭州中美华东制药有限公司 | 一种螺环化合物的盐型、晶型及其制备方法 |
| CN117940422A (zh) | 2021-08-31 | 2024-04-26 | 辉瑞大药厂 | 2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸,1,3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式 |
| CN115974851A (zh) * | 2021-10-14 | 2023-04-18 | 华领医药技术(上海)有限公司 | 2-氧代-3-氮杂双环[3.1.0]己烷衍生物 |
| WO2023111817A1 (en) | 2021-12-17 | 2023-06-22 | Pfizer Inc. | Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid |
| JP2024544794A (ja) * | 2021-12-24 | 2024-12-04 | エルジー・ケム・リミテッド | (s)-2-(2-メチルアゼチジン-1-イル)ピリミジン誘導体およびそれを含む医薬組成物 |
| CN114315494B (zh) * | 2021-12-29 | 2023-09-22 | 苏州楚凯药业有限公司 | 一种(s)-2-甲基氮杂环丁烷盐酸盐的制备方法 |
| US20250145619A1 (en) * | 2022-02-09 | 2025-05-08 | Youngene Therapeutics Co., Ltd | Khk inhibitor, preparation method therefor and use thereof |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| IL319392A (en) | 2022-10-18 | 2025-05-01 | Pfizer | Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations |
| AR132416A1 (es) | 2023-04-12 | 2025-06-25 | Centennial Therapeutics Llc | Compuestos de pirimidina disustituidos para la inhibición de la cetohexoquinasa |
| KR20260022334A (ko) | 2023-05-31 | 2026-02-19 | 센테니얼 테라퓨틱스, 엘엘씨 | 케토헥소키나제 억제를 위한 이환식 화합물 |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2025224648A1 (en) | 2024-04-26 | 2025-10-30 | Pfizer Inc. | Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980350A (en) | 1988-02-25 | 1990-12-25 | Merck & Co., Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
| DE4208254A1 (de) | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| CA2439152C (en) | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| WO2003072197A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Acc inhibitors |
| EA011086B9 (ru) | 2004-05-12 | 2012-08-30 | Пфайзер Продактс Инк. | Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv |
| GEP20094723B (en) | 2004-05-25 | 2009-07-10 | Pfizer Prod Inc | Tetraazabenzo [e] azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| EP2010520B1 (en) | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| WO2008024902A2 (en) | 2006-08-23 | 2008-02-28 | University Of Florida Research Foundation, Inc. | Targeting of fructokinase as therapy for cardiovascular disease, metabolic syndrome, and renal disease |
| WO2008065508A1 (en) | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Spiroketone acetyl-coa carboxylase inhibitors |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| JP5411867B2 (ja) * | 2007-10-11 | 2014-02-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規sEH阻害剤およびそれらの使用 |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
| EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CA2729581A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
| EP2326640A1 (en) * | 2008-07-30 | 2011-06-01 | Ranbaxy Laboratories Limited | Pyrrole carboxylic acid derivatives as antibacterial agents |
| ES2380408T3 (es) | 2008-08-28 | 2012-05-11 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| WO2010103437A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| CA2754523A1 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| MX2011010200A (es) * | 2009-04-08 | 2011-10-14 | Actelion Pharmaceuticals Ltd | 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp). |
| EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| GEP20135907B (en) | 2009-06-05 | 2013-08-12 | Pfizer | L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| KR101686913B1 (ko) * | 2009-08-13 | 2016-12-16 | 삼성전자주식회사 | 전자기기에서 이벤트 서비스 제공 방법 및 장치 |
| US8822447B2 (en) * | 2010-04-22 | 2014-09-02 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
| WO2012019188A2 (en) * | 2010-08-06 | 2012-02-09 | The Regents Of The University Of Colorado, A Body Corporate | Methods and compositions for the inhibition of fructokinase |
| CN102432598A (zh) * | 2010-09-29 | 2012-05-02 | 江苏恒瑞医药股份有限公司 | 三环化合物、其制备方法及其在医药上的应用 |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| EP3105331B1 (en) | 2014-02-11 | 2021-06-23 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
| TN2018000198A1 (en) * | 2015-12-29 | 2019-10-04 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
-
2016
- 2016-12-16 TN TNP/2018/000198A patent/TN2018000198A1/en unknown
- 2016-12-16 GE GEAP201614820A patent/GEP20207147B/en unknown
- 2016-12-16 CN CN201680077234.3A patent/CN108473469B/zh active Active
- 2016-12-16 SI SI201631206T patent/SI3397631T1/sl unknown
- 2016-12-16 MA MA43518A patent/MA43518B1/fr unknown
- 2016-12-16 UA UAA201807242A patent/UA121271C2/uk unknown
- 2016-12-16 SG SG11201804363UA patent/SG11201804363UA/en unknown
- 2016-12-16 CU CU2018000046A patent/CU24540B1/es unknown
- 2016-12-16 AU AU2016380920A patent/AU2016380920B2/en not_active Ceased
- 2016-12-16 RU RU2018123528A patent/RU2696269C1/ru active
- 2016-12-16 GE GEAP202014820A patent/GEAP202014820A/en unknown
- 2016-12-16 US US15/381,295 patent/US9809579B2/en active Active
- 2016-12-16 HR HRP20210769TT patent/HRP20210769T1/hr unknown
- 2016-12-16 WO PCT/IB2016/057728 patent/WO2017115205A1/en not_active Ceased
- 2016-12-16 HU HUE16823054A patent/HUE054380T2/hu unknown
- 2016-12-16 PT PT168230548T patent/PT3397631T/pt unknown
- 2016-12-16 KR KR1020187018089A patent/KR102073048B1/ko active Active
- 2016-12-16 MD MDE20181083T patent/MD3397631T2/ro not_active IP Right Cessation
- 2016-12-16 PE PE2018001204A patent/PE20181289A1/es unknown
- 2016-12-16 LT LTEP16823054.8T patent/LT3397631T/lt unknown
- 2016-12-16 PL PL16823054T patent/PL3397631T3/pl unknown
- 2016-12-16 EP EP16823054.8A patent/EP3397631B1/en active Active
- 2016-12-16 DK DK16823054.8T patent/DK3397631T3/da active
- 2016-12-16 JP JP2018533924A patent/JP6503515B2/ja active Active
- 2016-12-16 ES ES16823054T patent/ES2871251T3/es active Active
- 2016-12-16 RS RS20210654A patent/RS61896B1/sr unknown
- 2016-12-16 MX MX2018007755A patent/MX376072B/es active IP Right Grant
- 2016-12-22 CA CA2952466A patent/CA2952466C/en active Active
- 2016-12-27 UY UY0001037051A patent/UY37051A/es not_active Application Discontinuation
- 2016-12-28 TW TW105143483A patent/TWI653232B/zh active
-
2017
- 2017-10-11 US US15/729,885 patent/US10174007B2/en active Active
-
2018
- 2018-05-24 ZA ZA2018/03449A patent/ZA201803449B/en unknown
- 2018-06-13 SV SV2018005709A patent/SV2018005709A/es unknown
- 2018-06-19 CL CL2018001667A patent/CL2018001667A1/es unknown
- 2018-06-25 NI NI201800072A patent/NI201800072A/es unknown
- 2018-06-26 PH PH12018501375A patent/PH12018501375A1/en unknown
- 2018-06-27 EC ECSENADI201848517A patent/ECSP18048517A/es unknown
- 2018-06-27 CO CONC2018/0006714A patent/CO2018006714A2/es unknown
- 2018-06-28 IL IL260330A patent/IL260330B/en unknown
- 2018-12-06 US US16/211,283 patent/US20190106412A1/en not_active Abandoned
-
2020
- 2020-01-16 US US16/744,283 patent/US10787438B2/en active Active
- 2020-08-21 US US16/999,295 patent/US10988463B2/en active Active
-
2021
- 2021-03-23 US US17/209,780 patent/US11634410B2/en active Active
- 2021-05-06 CY CY20211100385T patent/CY1124389T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501375A1 (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
| MX2021004479A (es) | Agentes biologicos y su uso en plantas. | |
| UY34607A (es) | Plantas resistentes al glifosato y métodos asociados. | |
| MX2022001043A (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas. | |
| EA201690280A1 (ru) | Композиции и способы, относящиеся к выделенным эндофитам | |
| UY4235Q (es) | Configuración aplicada en zapato | |
| EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
| MX375438B (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| SA517390034B1 (ar) | مشتقات الكربوكساميدو بيروليدين وطرق تحضيرها واستخدامها | |
| EA201692534A1 (ru) | Способы лечения гипотонии | |
| HRP20180933T1 (hr) | 5-oksa-2-azabiciklo[2.2.2]oktan-4-il i 5-oksa-2-azabiciklo[2.2.1]heptan-4-il derivati kao taar1 modulatori | |
| WO2014140856A3 (en) | Mir-142 and antagonists thereof for treating disease | |
| UY4314Q (es) | Configuracion aplicada en zapato | |
| UY4233Q (es) | Configuración aplicada en zapato | |
| EA201700060A1 (ru) | Терапевтическое средство для кератоконъюнктивальных расстройств | |
| EA201690914A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| EA201691036A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| HUE041810T2 (hu) | Szinergisztikus hatásokkal rendelkezõ, mikrorészecskéket tartalmazó, szövegjavítást biztosító dermális mátrix, valamint elõállítási eljárása | |
| EA201800348A1 (ru) | Замещенные 3-азабицикло[3.1.0]гексаны в качестве ингибиторов кетогексокиназы | |
| UA97535U (xx) | Сорбційно-фільтруючий матеріал | |
| RU2013132326A (ru) | Способ лечения некробактериоза копыт у животных | |
| UY4461U (es) | Proceso constructivo modular | |
| CR20140456S (es) | Grúa de pórtico | |
| RU2014123181A (ru) | Средство, обладающее противовоспалительной и антиоксидантной активностью | |
| TH1601000712A (th) | สารประกอบและวิธีการสำหรับการปรับปรุงศักยภาพของพืช |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |